Curcuma as an anti-inflammatory component in treating osteoarthritis
- 17 November 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 43 (4) , 589-616
Abstract
Osteoarthritis (OA) is nowadays the most common musculoskeletal progressive condition. In recent decades, incidence and prevalence of OA have increased significantly. It is estimated that the prevalence of OA among adults older than 60 is 12%, affecting about 240 million people globally. The cause has not been fully elucidated, and therefore, there is no cure at the moment. It is a multifactorial degenerative disease with an inflammatory component mediated by numerous proinflammatory and anti-inflammatory cytokines, chemokines, and growth factors. OA is not yet fully understood; therefore, therapeutic interventions are aimed primarily at reducing symptoms and slowing the progression of joint destruction. Of the therapeutic options available, the most often prescribed are nonsteroidal antirheumatic drugs, which have numerous side effects. Therefore, a need for a safe, effective substance is differentiated, which will be used in adjuvant treatment, but also in disease prevention, and which will comparatively have no or fewer side effects. One such substance is curcumin, a hydrophobic polyphenol that forms the active component of the rhizome of the Curcuma longa plant. Several studies have shown its potent antioxidant and anti-inflammatory effect, non-toxicity, and safety at high daily doses. In addition to blocking chondrocyte apoptosis, curcumin also blocks the expression of cyclooxygenase, prostaglandin E-2 and proinflammatory cytokines in chondrocytes, potentially alleviating symptomatic diseases. Although there are significant variations in quality, methodology, and research results conducted on curcumin efficiency in OA treatment, curcumin is primarily recommended as systematic short-term and medium-term adjuvant therapy that reduces inflammatory biochemical factors. Reducing inflammation leads to better pain regulation and improved joint function, significantly reducing standard prescribed doses of drugs. The most researched daily doses of curcumin intake are 1000–2000 mg/day, which would also be the doses that most of the authors recommend. Further research is needed to determine the preventive role of curcumin in the pathogenesis of OA, the effects of long-term usage of curcumin in preventive purposes and treatment of osteoarthritis, as well as to determine optimal therapeutic dosages.Keywords
This publication has 35 references indexed in Scilit:
- Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPain Medicine, 2015
- Aging-related inflammation in osteoarthritisOsteoarthritis and Cartilage, 2015
- The role of inflammation-related genes in osteoarthritisOsteoarthritis and Cartilage, 2015
- Inflammation and intracellular metabolism: new targets in OAOsteoarthritis and Cartilage, 2015
- Inflammatory biomarkers in osteoarthritisOsteoarthritis and Cartilage, 2015
- A New Curcuma Extract (Flexofytol®) in Osteoarthritis: Results from a Belgian Real-Life ExperienceThe Open Rheumatology Journal, 2014
- Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double‐Blind Placebo‐Controlled TrialPhytotherapy Research, 2014
- In Vivo Luminescence Imaging of NF‐κB Activity and Serum Cytokine Levels Predict Pain Sensitivities in a Rodent Model of OsteoarthritisArthritis & Rheumatology, 2013
- OARSI recommendations for the management of hip and knee osteoarthritisOsteoarthritis and Cartilage, 2010
- Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytesInflammation Research, 2009